ANIP FY2025 SEC EDGAR DEF 14A #37 of 168 in industry

Ani Pharmaceuticals Inc CEO pay ratio

The CEO earned $10.3M in FY2025 against median worker pay of $89,954 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-09
Industry
Chemicals & Pharmaceuticals
Industry rank
#37/168

Data updated August 2026

Subscribe to Ani Pharmaceuticals Inc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
114:1
Moderate (Scale: 0–1000:1)
CEO pay
$10.3M
Median worker
$89,954

Answer first

Ani Pharmaceuticals Inc's FY2025 CEO total of $10.3M ranks #513 of 1,423 complete filings; its 114:1 pay ratio ranks #574. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $89,954. Industry placement uses the FY2025 SIC-28 peer cohort (# 37 of 168, 79th percentile - top quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#513
$10.3M of 1,423 FY2025
Ratio rank
#574
114:1 of 1,423
Industry pct
79th
top quartile of industry peers by pay ratio

How Ani Pharmaceuticals Inc ranks nationally

Ani Pharmaceuticals Inc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$10,254,756 Top 36% higher than 64% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). This entry sits in this band. $12,500,000–$15,000,000: 91 companies (6%). Above this entry. $15,000,000–$17,500,000: 88 companies (6%). Above this entry. $17,500,000–$20,000,000: 54 companies (4%). Above this entry. $20,000,000–$22,500,000: 24 companies (2%). Above this entry. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Ani Pharmaceuticals Inc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($10.3M) against pay ratio (114:1) for Ani Pharmaceuticals Inc (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both3092907.18475861.013858815.019241768.924624722.938.4:158.2:178:197.8:1117.6:1CEO total payPay ratio (CEO : median worker)Ani Pharmaceuticals Inc, CEO total pay: 10254756 · Pay ratio (CEO : median worker): 114:1Ani Pharmaceuticals IncPerimeter Solutions, Inc., CEO total pay: 8062080 · Pay ratio (CEO : median worker): 114:1Perimeter Solutions, Inc.Biogen Inc., CEO total pay: 23646004 · Pay ratio (CEO : median worker): 113:1Biogen Inc.Cronos Group Inc., CEO total pay: 4071626 · Pay ratio (CEO : median worker): 112:1Cronos Group Inc.Biomarin Pharmaceutical Inc, CEO total pay: 21927563 · Pay ratio (CEO : median worker): 109:1Biomarin Pharmaceutical Inc
Ani Pharmaceuticals Inc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Ani Pharmaceuticals Inc's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Ani Pharmaceuticals Inc

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
114:1
FY2025
vs prior FY
+7:1
from FY2024 107:1
CEO $ YoY
+16%
$10.3M latest
Filings shown
5
FY2021–2025
Ani Pharmaceuticals Inc CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $403K - $50,403 8:1 -
2022 $57K -86% $57,385 1:1 -7:1
2023 $8.1M +14009% $62,765 129:1 +128:1
2024 $8.9M +9.6% $82,949 107:1 -22:1
2025 $10.3M +16% $89,954 114:1 +7:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1023024, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
114:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$10.3M
Companies in Industry
168
vs. Industry Median
Above
#37 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Ani Pharmaceuticals Inc: MID · HEAVY pay ratio

Ani Pharmaceuticals Inc's FY2025 ratio 114:1 ranks #37 of 168 Chemicals & Pharmaceuticals filers (79th percentile). the CEO earned 114× the median employee ($89,954) in FY2025.

Median employee $89,954 (HIGH-MED); MID · HEAVY stamps put about 114 median-wage years per CEO year.

CEO Total Pay

$10.3M

FY2025 Summary Compensation, above median

Pay Ratio

114:1

Near industry median

Ani Pharmaceuticals Inc in the higher Chemicals & Pharmaceuticals third

Ani Pharmaceuticals Inc's FY2025 ratio 114:1 ranks #37 of 168 Chemicals & Pharmaceuticals filers (79th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Ani Pharmaceuticals Inc's $10.3M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #513 and ratio rank #574 split - treat 114:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$10.3M
Median Employee Pay
$89,954
Pay Ratio
114:1
Filing Date
2026-04-09

Company Info

Ticker
ANIP
CIK
1023024
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1023024, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Ani Pharmaceuticals Inc's FY2025 ratio 114:1 ranks #37 of 168 Chemicals & Pharmaceuticals filers (79th percentile).

Read with Ani Pharmaceuticals Inc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MID · HEAVY · HIGH-MED.

Yelp Inc · HEAVY

ABS(ceo_total_comp) peer at $10.3M (Δ $2K heavier vs Ani Pharmaceuticals Inc); MID · HIGH-MED vs this page's MID · HEAVY · HIGH-MED.
AdaptHealth Corp. · HEAVY

ABS(ceo_total_comp) peer at $10.2M (Δ $6K lighter vs Ani Pharmaceuticals Inc); STEEP · PAR-MED vs this page's MID · HEAVY · HIGH-MED.
First Citizens Bancshares Inc /de/ · HEAVY

ABS(ceo_total_comp) peer at $10.2M (Δ $7K lighter vs Ani Pharmaceuticals Inc); MID · ELITE-MED vs this page's MID · HEAVY · HIGH-MED.
Disc Medicine, Inc. · HEAVY

ABS(ceo_total_comp) peer at $10.3M (Δ $9K heavier vs Ani Pharmaceuticals Inc); FLOOR · ELITE-MED vs this page's MID · HEAVY · HIGH-MED.
Perimeter Solutions, Inc. (SIC 28 pole)

Perimeter Solutions, Inc. stamps MID · HEAVY nearest in-SIC by ABS(pay_ratio) to Ani Pharmaceuticals Inc's MID filing.
National dual ranks · #513/#574

Ani Pharmaceuticals Inc's FY2025 package sits #513 by CEO dollars and #574 by ratio under HEAVY · MID.
Comp structure · HEAVY

Ani Pharmaceuticals Inc's HEAVY CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for Ani Pharmaceuticals Inc (CIK 1023024), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.